Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Cypress Bioscience is a medical service provider that facilitates individualized patient care. The service provides its patients with therapeutic and personalized medical services in a variety of needs such as isolated areas of pain, rheumatology, and physical medicine and rehabilitation. It also addresses challenging disorders such as fibromyalgia and rheumatoid arthritis. Furthermore, the organization engages in the development of drugs such as Savella, a milnacipran HCI for the treatment of fibromyalgia, as well as Prosorba, a medical device for rheumatoid arthritis. Cypress Bioscience was founded in 1981 and is based in San Diego, California.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Amarin Neuroscience Ltd. develops pharmaceutical products for depression and neurological disorders. The company was previously known as laxdale Ltd. The company provides clinical supplies of Miraxion through its sub-contractors. The company was founded in 1997 and is headquartered in Stirling, UK.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Asahi Kasei Pharma Corp., a subsidiary of Asahi Kasei Corp., is a company headquartered in Tokyo, Japan, that functions as an alternative investment manager. The firm was founded in 2003.\nThe company says this about itself: Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company, that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics.

Chemo Iberica, S.A. manufactures and distributes generic medicines. It offers pharmaceuticals; agrochemicals, including insecticides, fungicides, herbicides, and micronutrients for agrochemical formulations; oncology drugs; and veterinary drugs for nutrition and animal health, such as antibiotics, anthelmintics, antiinflammatory, antiparasities, coccidiostatic, and chemotherapeutical drugs. The company offers its products in Asian markets, including South Korea, the Philippines, Malaysia, Vietnam, Thailand, and Pakistan, as well as exported to European countries, the United States, South America, and Canada. It has a strategic alliance with Fosum Pharma. The company was founded in 1940 and is headquartered in Madrid, Spain with additional offices in Spain, Switzerland, Hungary, India, China, Italy, and Brazil. It has production facilities in Europe, Asia, and Latin America.

Sichuan Credit Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of products related to central nervous system. Its products include capsules, tablets, freeze-dried powder injections, water injections, anti-tumor solid preparations, and traditional Chinese medicines. The company was founded on April 20, 2000 and is headquartered in Luzhou, China.

Arch Pharmalabs is a pharmaceutical company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. We have evolved our business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to our offerings, which has significant potential for the growth of our business.

Glenmark Generics Ltd., part of Glenmark Pharmaceuticals Ltd., is a company headquartered in Mumbai, India. The firm manufactures and markets generic drugs.

NTG Nordic Transport Group A/S is an international forwarding and logistics provider for road freight, sea freight, air freight and contract logistics. It operates through two segments: Road & Logistics and Air & Ocean. The Road & Logistics segment provides transport and warehousing solutions with a geographical focus on Europe. The Air & Ocean segment provides international air and ocean freight services, including project transports. The company was founded by Jørgen Buus Lassen in 1989 and is headquartered in Hvidovre, Denmark.

Established in 1996, Shanghai Modern Pharmaceutical Co., Ltd. is a high-tech enterprise in the pharmaceutical industry founded by the Chinese Academy of Engineering, specializing in the manufacture of new pharmaceutical preparations. It was listed on the Shanghai Stock Exchange on June 16, 2004 (stock code: 600420) , Securities abbreviation: Hyundai Pharmaceutical). In April 2010, he entered China Pharmaceutical Group Co., Ltd.

AHN-GOOK PHARMACEUTICAL Co., Ltd. engages in the development, production, and sale of pharmaceutical products. Its products include health function food, medical equipment, quasi-drugs, over-the-counter drugs, ethical drugs and recommended products such as Binosto effervescent tablet, Tobicom-S soft capsule, Levotension tablet and TobicomKid Q-10 chewable tablets. The company was founded by Noh Jong-Hyeong on September 16, 1955 and is headquartered in Seoul, South Korea.

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

Jiangsu Diqi Pharmaceutical Technology Co., Ltd., established on 2018-08-14, Business scope includes pharmaceutical,chemical product(except dangerous goods)technology R & D,technology transfer,technical consulting,Technical Services,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)